Your browser doesn't support javascript.
loading
Peripheral inflammatory markers indicate microstructural damage within periventricular white matter hyperintensities in Alzheimer's disease: A preliminary report.
Swardfager, Walter; Yu, Di; Ramirez, Joel; Cogo-Moreira, Hugo; Szilagyi, Gregory; Holmes, Melissa F; Scott, Christopher J M; Scola, Gustavo; Chan, Pak C; Chen, Jialun; Chan, Parco; Sahlas, Demetrios J; Herrmann, Nathan; Lanctôt, Krista L; Andreazza, Ana C; Pettersen, Jacqueline A; Black, Sandra E.
Afiliação
  • Swardfager W; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, Canada; LC Campbell Cognitiv
  • Yu D; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, Canada; LC Campbell Cognitiv
  • Ramirez J; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, Canada; LC Campbell Cognitive Neurology Unit, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Cogo-Moreira H; Departamento Psiquiatria, Universidade Federal de São Paulo, São Paulo, São Paulo, Brazil.
  • Szilagyi G; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, Canada; LC Campbell Cognitive Neurology Unit, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Holmes MF; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, Canada; LC Campbell Cognitive Neurology Unit, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Scott CJ; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, Canada; LC Campbell Cognitive Neurology Unit, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Scola G; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Anxiety and Mood Disorders Department, Centre for Addictions and Mental Health, Toronto, Ontario, Canada.
  • Chan PC; Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Chen J; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Chan P; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
  • Sahlas DJ; Department of Medicine (Neurology Division), McMaster University, Hamilton, Ontario, Canada.
  • Herrmann N; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
  • Lanctôt KL; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, Canada; University Health Ne
  • Andreazza AC; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Anxiety and Mood Disorders Department, Centre for Addictions and Mental Health, Toronto, Ontario, Canada.
  • Pettersen JA; Department of Medicine (Neurology Division), University of Northern British Columbia, British Columbia, Canada.
  • Black SE; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada; Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, Toronto, Ontario, Canada; LC Campbell Cognitive Neurology Unit, Sunnybrook Research Institute, Toronto, Ontario, Canada; Department of Cli
Alzheimers Dement (Amst) ; 7: 56-60, 2017.
Article em En | MEDLINE | ID: mdl-28275700
ABSTRACT

INTRODUCTION:

White matter hyperintensities (WMH) presumed to reflect cerebral small vessel disease and increased peripheral inflammatory markers are found commonly in Alzheimer's disease (AD), but their interrelationships remain unclear.

METHODS:

Inflammatory markers were assayed in 54 elderly participants (n = 16 with AD). Periventricular WMH were delineated from T1, T2/proton density, and fluid-attenuated magnetic resonance imaging using semiautomated fuzzy lesion extraction and coregistered with maps of fractional anisotropy (FA), a measure of microstructural integrity assessed using diffusion tensor imaging.

RESULTS:

Mean FA within periventricular WMH was associated with an inflammatory factor consisting of interleukin (IL)-1ß, tumor necrosis factor, IL-10, IL-21, and IL-23 in patients with AD (ρ = -0.703, P = .002) but not in healthy elderly (ρ = 0.217, P = .190). Inflammation was associated with greater FA in deep WMH in healthy elderly (ρ = 0.425, P = .008) but not in patients with AD (ρ = 0.174, P = .520).

DISCUSSION:

Peripheral inflammatory markers may be differentially related to microstructural characteristics within the white matter affected by cerebral small vessel disease in elders with and without AD.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article